These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Yang Y; Guo Y; Yin D; Zheng Y; Wu S; Zhu D; Hu F Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33139291 [TBL] [Abstract][Full Text] [Related]
6. In vitro activity of cefepime/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals. Bhagwat SS; Legakis NJ; Skalidis T; Loannidis A; Goumenopoulos C; Joshi PR; Shrivastava R; Palwe SR; Periasamy H; Patel MV; Chatzipanagiotou S; Diagn Microbiol Infect Dis; 2021 Jul; 100(3):115327. PubMed ID: 33744624 [TBL] [Abstract][Full Text] [Related]
7. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa. Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000 [TBL] [Abstract][Full Text] [Related]
8. Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres. Khan Z; Iregui A; Landman D; Quale J J Antimicrob Chemother; 2019 Oct; 74(10):2938-2942. PubMed ID: 31298277 [TBL] [Abstract][Full Text] [Related]
10. Activity of cefepime/zidebactam (WCK 5222) against 'problem' antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory. Mushtaq S; Garello P; Vickers A; Woodford N; Livermore DM J Antimicrob Chemother; 2021 May; 76(6):1511-1522. PubMed ID: 33760082 [TBL] [Abstract][Full Text] [Related]
11. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. Livermore DM; Mushtaq S; Warner M; Vickers A; Woodford N J Antimicrob Chemother; 2017 May; 72(5):1373-1385. PubMed ID: 28158732 [TBL] [Abstract][Full Text] [Related]
12. Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates. Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848013 [TBL] [Abstract][Full Text] [Related]
13. Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate. Pan X; Zhao X; Song Y; Ren H; Tian Z; Liang Q; Jin Y; Bai F; Cheng Z; Feng J; Wu W Microbiol Spectr; 2022 Feb; 10(1):e0267821. PubMed ID: 35196805 [TBL] [Abstract][Full Text] [Related]
14. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the Yin D; Wu S; Yang Y; Shi Q; Dong D; Zhu D; Hu F; Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30617091 [TBL] [Abstract][Full Text] [Related]
15. Multicenter surveillance of Jean SS; Ko WC; Lu MC; Lee WS; Hsueh PR; Expert Rev Anti Infect Ther; 2022 Jun; 20(6):941-953. PubMed ID: 34933656 [TBL] [Abstract][Full Text] [Related]
16. Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022). Sader HS; Carvalhaes CG; Kimbrough JH; Mendes RE; Castanheira M Int J Antimicrob Agents; 2024 Apr; 63(4):107113. PubMed ID: 38354826 [TBL] [Abstract][Full Text] [Related]
17. Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. Sader HS; Carvalhaes CG; Arends SJR; Castanheira M; Mendes RE J Antimicrob Chemother; 2021 Feb; 76(3):659-666. PubMed ID: 33276387 [TBL] [Abstract][Full Text] [Related]
18. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones. Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289035 [TBL] [Abstract][Full Text] [Related]
19. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives? Le Terrier C; Freire S; Nordmann P; Poirel L Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):339-354. PubMed ID: 38095831 [TBL] [Abstract][Full Text] [Related]
20. Activity of β-lactam plus β-lactam-enhancer combination cefepime/zidebactam against Klebsiella pneumoniae harbouring defective OmpK35/36 porins and carbapenemases. Joshi P; Shrivastava R; Bhagwat S; Patel M Diagn Microbiol Infect Dis; 2021 Oct; 101(2):115481. PubMed ID: 34332307 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]